Coronary Artery Disease Market Report 2026

The coronary artery disease market size has grown rapidly in recent years. It will grow from $31.88 billion in 2025 to $35.27 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to high prevalence of cardiovascular disease, sedentary lifestyles, tobacco consumption, limited preventive care awareness, hospital-centric treatment models.

The coronary artery disease market size is expected to see rapid growth in the next few years. It will grow to $53.97 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to aging global population, increasing obesity rates, improved diagnostic technologies, growth of preventive cardiology, rising healthcare access. Major trends in the forecast period include increasing focus on early disease detection, rising use of combination drug therapies, growth of lifestyle modification programs, expansion of minimally invasive treatments, integration of cardiac rehabilitation services.

The increasing prevalence of coronary artery disease is expected to drive the growth of the coronary artery disease market in the coming years. Coronary artery disease (CAD) is a medical condition marked by the narrowing or blockage of the coronary arteries that supply blood to the heart muscle. The incidence of coronary artery disease is rising due to factors such as dietary changes, higher stress levels, physical inactivity, obesity, aging populations, and other lifestyle-related factors. Coronary artery disease is managed using medications such as clopidogrel, ticagrelor, warfarin, and heparin, along with interventional procedures including coronary artery bypass grafting, angioplasty, and stenting. For example, in October 2025, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 2,700 acute coronary events occurred among First Nations people aged 25 years and older in 2023. After adjusting for age differences in the population, the rate of these events was 2.8 times higher than that observed among non-Indigenous people. Therefore, the rising prevalence of coronary artery disease is anticipated to boost market growth during the forecast period.

Companies operating in the coronary artery disease market are increasingly focusing on the development of innovative products such as drug-coated balloon catheters to strengthen their market position and drive revenue growth. Drug-coated balloon catheters are interventional cardiology devices used to treat narrowed or blocked blood vessels, particularly in patients with coronary artery disease or peripheral artery disease. For instance, in March 2024, Boston Scientific Corporation, a US-based medical device company, announced that it received US Food and Drug Administration approval for the AGENT Drug-Coated Balloon, which is indicated for the treatment of coronary in-stent restenosis in patients with coronary artery disease. In-stent restenosis refers to the re-narrowing or blockage of a previously stented vessel due to plaque buildup or scar tissue formation. The AGENT drug-coated balloon provides a targeted treatment option for this complex condition and addresses a significant unmet medical need. It is specifically designed for use in in-stent restenosis as well as previously untreated small-vessel coronary disease and is available across Europe, parts of the Asia Pacific region, and Latin America.

In April 2023, Abbott Laboratories, a US-based medical devices and healthcare company, acquired Cardiovascular Systems Inc. for $890 million. This acquisition was intended to expand Abbott’s portfolio with complementary solutions for the treatment of vascular disease. Cardiovascular Systems Inc. is a US-based medical device company that focuses on developing and commercializing innovative technologies for the treatment of peripheral and coronary artery disease.

Major companies operating in the coronary artery disease market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Kowa Pharmaceuticals America Inc., Barr Pharmaceuticals Inc., AdvanceCor GmbH, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) e.V.

North America was the largest region in the coronary artery disease market in 2025. The regions covered in the coronary artery disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coronary artery disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the coronary artery disease market by increasing costs of imported diagnostic devices, cardiovascular drugs, surgical equipment, and consumables. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported technologies, while Asia-Pacific faces higher diagnostic costs. These tariffs are increasing treatment expenses. However, they are also driving domestic pharmaceutical production and local medical device manufacturing.

The coronary artery disease market research report is one of a series of new reports that provides coronary artery disease market statistics, including coronary artery disease industry global market size, regional shares, competitors with a coronary artery disease market share, detailed coronary artery disease market segments, market trends and opportunities, and any further data you may need to thrive in the coronary artery disease industry. This coronary artery disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Coronary artery disease (CAD) is a medical condition that affects the coronary arteries, which are the blood vessels responsible for supplying oxygen-rich blood to the heart muscle. Coronary artery disease develops when these arteries become narrowed or blocked as a result of plaque accumulation, which consists of cholesterol, fat, calcium, and other substances.

The primary treatment options for coronary artery disease include medication, surgery, additional therapies, and others. Medications are substances used to prevent, manage, or treat medical conditions and include drugs such as clopidogrel, atorvastatin, metoprolol, lisinopril, losartan, amlodipine, nitroglycerine, and other medications. Diagnosis of coronary artery disease involves procedures such as electrocardiogram, echocardiogram, stress testing, cardiac catheterization, heart CT scans, and other diagnostic methods. These treatments and diagnostics are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels and are utilized by hospitals, specialty clinics, and other healthcare providers.

The coronary artery disease market includes revenues earned by entities by providing coronary angioplasty, coronary artery bypass and heart transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.